This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

NICE guidance - Ustekinumab for treating moderately to severely active ulcerative colitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

NICE guidance states (1):

  • Ustekinumab is recommended as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if:
    • a tumour necrosis factor-alpha inhibitor has failed (that is the disease has responded inadequately or has lost response to treatment) or
    • a tumour necrosis factor-alpha inhibitor cannot be tolerated or is not suitable, and
    • a the company provides ustekinumab at the same price or lower than that agreed with the Commercials Medicines Unit

Ustekinumab (1,2,3,4)

  • a non-selective anti-interleukin (IL)12/23 p40 monoclonal antibody
  • appears to have a swift and lasting effect with potential for mucosal healing and systemic anti-inflammatory response with no known immunogenicity
  • may be preferred over anti-TNF therapy in older patients with increased risk for infections and malignancy, as concurrent immunosuppression may not be required due to its low immunogenicity
  • is used in combination with methotrexate, 6-mercaptopurine, azathioprine, or steroids, which may not affect the safety or efficacy of ustekinumab
  • is not approved for use in pregnancy or breastfeeding; it may pass through the placenta or milk
  • possible side effects include:
    • an increased risk of infections from a reduced ability to mount an immune response
    • reactivation of latent infections which involves an increased risk of infections
    • serious microbial infections include TB, viral, and fungal diseases
    • patients who are predisposed to genetic variation in the proteins IL12 and IL-23 are at a higher risk for disseminated (systemic) infectious diseases such as Salmonella, Mycobacteria, and Bacillus Calmette-Guerin (BCG)
  • may provide clinical benefit in a range of settings in patients with ulcerative colitis, even for those with multiple treatment failures, which are relatively common in daily clinical practice (4)

Reference:

  • NICE (17 June 2020). Ustekinumab for treating moderately to severely active ulcerative colitis
  • Chen AY, Oz HS. Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab. Diseases. 2019;7(4):55.
  • Ochsenkuhn T, Tillack C, Szokodi D, Janelidze S, Schnitzler F. Clinical outcomes with ustekinumab as rescue treatment in therap-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J. 2020;8(1):91-98.
  • Biancone L, Ardizzone S, Armuzzi A, Castiglione F, D'Inca R, Danese S, Daperno M, Gionchetti P, Rizzello F, Scribano ML, Vecchi M, Orlando A. Ustekinumab for treating ulcerative colitis: an expert opinion. Expert Opin Biol Ther. 2020 Nov;20(11):1321-1329.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.